Browse GANC

Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF13802 Galactose mutarotase-like
PF01055 Glycosyl hydrolases family 31
Function

Has alpha-glucosidase activity.

> Gene Ontology
 
Biological Process GO:0000023 maltose metabolic process
GO:0005984 disaccharide metabolic process
GO:0009311 oligosaccharide metabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044723 single-organism carbohydrate metabolic process
Molecular Function GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds
GO:0004558 alpha-1,4-glucosidase activity
GO:0015926 glucosidase activity
GO:0016798 hydrolase activity, acting on glycosyl bonds
GO:0030246 carbohydrate binding
GO:0032450 maltose alpha-glucosidase activity
GO:0090599 alpha-glucosidase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00052 Galactose metabolism
hsa00500 Starch and sucrose metabolism
hsa01100 Metabolic pathways
Reactome -
Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GANC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GANC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GANC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7180.03
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0270.366
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4980.538
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1040.74
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3460.862
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.20.935
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0140.962
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4220.751
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4840.753
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2070.838
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7780.598
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2450.00499
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GANC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GANC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GANC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GANC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GANC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GANC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GANC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGANC
Nameglucosidase, alpha; neutral C
Aliases Neutral alpha-glucosidase C
Chromosomal Location15q15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GANC collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GANC.
ID Name Drug Type Targets #Targets
DB00491MiglitolSmall MoleculeGAA, GANAB, GANC, MGAM4